Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lutetium-177 PSMA-I&T |
Synonyms | |
Therapy Description |
Lutetium-177 PSMA-I&T is a radioconjugate comprising the radionuclide Lu 177 linked to a PSMA inhibitor for imaging and therapy (PSMA I&T), which potentially inhibits tumor growth (PMID: 26089548). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lutetium-177 PSMA-I&T | 177Lu-labeled PSMA I&T|Lu-177-PSMA-I&T | Lutetium-177 PSMA-I&T is a radioconjugate comprising the radionuclide Lu 177 linked to a PSMA inhibitor for imaging and therapy (PSMA I&T), which potentially inhibits tumor growth (PMID: 26089548). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06259123 | Phase II | Lutetium-177 PSMA-I&T | Neoadjuvant PSMA-RLT in Oligometastatic PCa | Recruiting | AUT | 0 |
NCT06220188 | Phase II | Lutetium-177 PSMA-I&T | PSMA-RLT in Biochemically Recurrent PCa | Recruiting | AUT | 0 |
NCT05383079 | Phase Ib/II | Lutetium-177 PSMA-I&T | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer: Phase I/II Study (AlphaBet) | Recruiting | AUS | 0 |